Is GSK3β a molecular target of chloroquine treatment against COVID-19?

被引：9
作者：
Embi, Mohammed Noor [1 ]
Ganesan, Nagesswary [1 ]
Sidek, Hasidah Mohd [1 ]
机构：
[1] Univ Kebangsaan Malaysia, Dept Biol Sci & Biotechnol, Fac Sci & Technol, Ukm Bangi 43600, Selangor, Malaysia
来源：
DRUG DISCOVERIES AND THERAPEUTICS | 2020年 / 14卷 / 02期
关键词：
Chloroquine; COVID-19; GSK3; beta; anti-inflammatory; GLYCOGEN-SYNTHASE KINASE-3;
D O I：
10.5582/ddt.2020.03010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The recent clinical trial reports pertaining to the efficacy of chloroquine and hydroxychloroquine against COVID-19 albeit yet to be validated with larger clinical trials, have sparked much interest globally to evaluate whether this anti-malarial drug can be repurposed for the treatment of COVID-19. In addition to its anti-viral activity, the anti-inflammatory activity of chloroquine may also contribute to its efficacy. Based on our data obtained from an animal infection model of melioidosis (a disease caused by the bacteria Burkholderia pseudomallei), treatment with chloroquine can result in the phosphorylation and consequent inhibition of glycogen synthase kinase-3 beta (GSK3 beta. This serine/threonine protein kinase is now recognised as a point of convergence for host inflammatory response. In view of this, it is plausible that the mechanism for the anti-inflammatory effect of chloroquine against COVID-19 involves inhibition of host GSK3 beta.
引用
收藏
页码：107 / 108
页数：2
相关论文
共 9 条
[1]   Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases [J].
Beurel, Eleonore ;
Grieco, Steven F. ;
Jope, Richard S. .
PHARMACOLOGY & THERAPEUTICS, 2015, 148 :114-131
[2]   GLYCOGEN-SYNTHASE KINASE-3 FROM RABBIT SKELETAL-MUSCLE - SEPARATION FROM CYCLIC-AMP-DEPENDENT PROTEIN-KINASE AND PHOSPHORYLASE-KINASE [J].
EMBI, N ;
RYLATT, DB ;
COHEN, P .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1980, 107 (02) :519-527
[3]  
Ganesan N, 2018, TROP BIOMED, V35, P709
[4]  
Ganesan N, 2020, TROP BIOMED
[5]   Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [J].
Gao, Jianjun ;
Tian, Zhenxue ;
Yang, Xu .
BIOSCIENCE TRENDS, 2020, 14 (01) :72-73
[6]   Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [J].
Gautret, Philippe ;
Lagier, Jean-Christophe ;
Parola, Philippe ;
Van Thuan Hoang ;
Meddeb, Line ;
Mailhe, Morgane ;
Doudier, Barbara ;
Courjon, Johan ;
Giordanengo, Valerie ;
Vieira, Vera Esteves ;
Dupont, Herve Tissot ;
Honore, Stephane ;
Colson, Philippe ;
Chabriere, Eric ;
La Scola, Bernard ;
Rolain, Jean-Marc ;
Brouqui, Philippe ;
Raoult, Didier .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
[7]   Lithium chloride inhibits the coronavirus infectious bronchitis virus in cell culture [J].
Harrison, Sally M. ;
Tarpey, Ian ;
Rothwell, Lisa ;
Kaiser, Pete ;
Hiscox, Julian A. .
AVIAN PATHOLOGY, 2007, 36 (02) :109-114
[8]  
Nowak Jan K, 2020, F1000Res, V9, P93, DOI 10.12688/f1000research.22299.2
[9]   Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review [J].
Xu, M. ;
Wang, S. L. ;
Zhu, L. ;
Wu, P. Y. ;
Dai, W. B. ;
Rakesh, K. P. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 :448-470
1